Home
MRK
MRK News

Latest Merck & Company Inc. (new) (MRK) News on January 22, 2025

Earnings Season Scorecard and Fresh Analyst Reports for Chevron, Merck & Others

Zacks

a day ago

Earnings Season Scorecard and Fresh Analyst Reports for Chevron, Merck & Others

Why WEC Energy, Fifth Third Bancorp And Merck Are Winners For Passive Income

Benzinga

2 days ago

Why WEC Energy, Fifth Third Bancorp And Merck Are Winners For Passive Income

Merck & Co., Inc. (MRK): A Bull Case Theory

Insider Monkey

2 days ago

Merck & Co., Inc. (MRK): A Bull Case Theory

Jim Cramer on Merck & Co., Inc. (MRK): ‘Right Now, The Stock’s Well-ensconced A Few Points Around 52-week Low’

Insider Monkey

2 days ago

Jim Cramer on Merck & Co., Inc. (MRK): ‘Right Now, The Stock’s Well-ensconced A Few Points Around 52-week Low’

Is Merck & Co., Inc. (MRK) the Best Cheap Stock to Buy for 2025?

Insider Monkey

3 days ago

Is Merck & Co., Inc. (MRK) the Best Cheap Stock to Buy for 2025?

Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year

Yahoo Finance

4 days ago

Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

TipRanks

4 days ago

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

Medicare to negotiate prices on 15 drugs, including Ozempic

Yahoo Finance Video

4 days ago

Medicare to negotiate prices on 15 drugs, including Ozempic

Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

Yahoo Finance

5 days ago

Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Zacks

5 days ago

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?

Zacks

5 days ago

Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?

Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4

Business Wire

6 days ago

Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4

Jim Cramer on Merck & Co., Inc. (MRK): ‘Down Very Badly’

Insider Monkey

7 days ago

Jim Cramer on Merck & Co., Inc. (MRK): ‘Down Very Badly’

Argus Research

7 days ago

Portfolio Selector for January, 2025

Jim Cramer Says Merck & Co., Inc. (MRK) Is ‘Getting Pummeled’

Insider Monkey

7 days ago

Jim Cramer Says Merck & Co., Inc. (MRK) Is ‘Getting Pummeled’

JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning

BioPharma Dive

8 days ago

JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning

Merck Races to Launch Subcutaneous Keytruda Amid Looming Patent Expiry for IV Version

GuruFocus.com

8 days ago

Merck Races to Launch Subcutaneous Keytruda Amid Looming Patent Expiry for IV Version

Merck is broadening its pipeline as Keytruda’s patent cliff looms

Pharma Voice

8 days ago

Merck is broadening its pipeline as Keytruda’s patent cliff looms

Is Merck & Co., Inc. (MRK) the Most Reliable Dividend Stock to Buy According to Hedge Funds?

Insider Monkey

9 days ago

Is Merck & Co., Inc. (MRK) the Most Reliable Dividend Stock to Buy According to Hedge Funds?

Merck Insiders Sold US$6.4m Of Shares Suggesting Hesitancy

Simply Wall St.

10 days ago

Merck Insiders Sold US$6.4m Of Shares Suggesting Hesitancy

Cramer on Merck & Co. (MRK): Trading Like a Value Trap Despite Strong Fundamentals

Insider Monkey

11 days ago

Cramer on Merck & Co. (MRK): Trading Like a Value Trap Despite Strong Fundamentals

Medicare drug prices nearly double, surpassing inflation: AARP

Yahoo Finance Video

11 days ago

Medicare drug prices nearly double, surpassing inflation: AARP

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Investor's Business Daily

13 days ago

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Simply Wall St.

14 days ago

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Merck’s GARDASIL® Receives Expanded Approval for Males in China

Business Wire

14 days ago

Merck’s GARDASIL® Receives Expanded Approval for Males in China

MT Newswires

14 days ago

Truist Securities Downgrades Merck to Hold From Buy, Adjusts Price Target to $110 From $130

WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million

The Wall Street Journal

15 days ago

WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million

Argus Research

16 days ago

Weekly Stock List

Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

16 days ago

Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal

Benzinga

20 days ago

UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

20 days ago

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

The 5 worst-performing stocks on the Dow Jones Industrial Average in 2024

TheStreet

21 days ago

The 5 worst-performing stocks on the Dow Jones Industrial Average in 2024

Is Merck & Co., Inc. (MRK) Among the Best Low Volatility Stocks to Buy Right Now?

Insider Monkey

21 days ago

Is Merck & Co., Inc. (MRK) Among the Best Low Volatility Stocks to Buy Right Now?

2 High-Yield Dividend Stocks to Buy Early in 2025

Motley Fool

22 days ago

2 High-Yield Dividend Stocks to Buy Early in 2025

Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79%

Simply Wall St.

22 days ago

Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79%

Is Merck & Co., Inc. (MRK) the Best Pharma Dividend Stock to Buy In 2024?

Insider Monkey

22 days ago

Is Merck & Co., Inc. (MRK) the Best Pharma Dividend Stock to Buy In 2024?

Merck & Co. Inc. (MRK): Billionaire D.E. Shaw Is Bullish On This Stock Right Now

Insider Monkey

a month ago

Merck & Co. Inc. (MRK): Billionaire D.E. Shaw Is Bullish On This Stock Right Now

Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals?

Simply Wall St.

a month ago

Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals?

3 biggest catalysts expected for healthcare in 2025

Yahoo Finance Video

a month ago

3 biggest catalysts expected for healthcare in 2025

Discover US Dividend Stocks For December 2024

Simply Wall St.

a month ago

Discover US Dividend Stocks For December 2024

Personalis price target raised to $8 from $7 at BTIG

TipRanks

a month ago

Personalis price target raised to $8 from $7 at BTIG

Merck closes exclusive global license agreement for LM-299 from LaNova Medicines

TipRanks

a month ago

Merck closes exclusive global license agreement for LM-299 from LaNova Medicines

Investing.com

a month ago

BMO cuts rating on Merck and Biogen, on lack of near term catalyst

Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain

Simply Wall St.

a month ago

Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Zacks

a month ago

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now?

Insider Monkey

a month ago

Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now?

Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody

Business Wire

a month ago

Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody

MT Newswires

a month ago

BMO Capital Downgrades Merck & Co. to Market Perform From Outperform, Adjusts Price Target to $105 From $136

Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials

Benzinga

a month ago

Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials

A venture firm breathes new life into an old NGM drug

BioPharma Dive

a month ago

A venture firm breathes new life into an old NGM drug

Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug

Zacks

a month ago

Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug

MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset

Pharmaceutical Technology

a month ago

MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

Business Wire

a month ago

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In?

Insider Monkey

a month ago

Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In?

Merck’s RSV antibody could soon paddle into the rough waters of a crowded market

Pharma Voice

a month ago

Merck’s RSV antibody could soon paddle into the rough waters of a crowded market

Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else

Investor's Business Daily

a month ago

Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else

What's Going On With Viking Therapeutics Stock On Wednesday?

Benzinga

a month ago

What's Going On With Viking Therapeutics Stock On Wednesday?

Elon Musk, Netflix fined, Merck's GLP-1 deal: Market Minute

Yahoo Finance Video

a month ago

Elon Musk, Netflix fined, Merck's GLP-1 deal: Market Minute

Merck to End Development of Two Cancer Candidates: Time to Sell?

Zacks

a month ago

Merck to End Development of Two Cancer Candidates: Time to Sell?

Strong Fundamentals And Weight Loss Entry Make Merck (MRK) A Buy

Insider Monkey

a month ago

Strong Fundamentals And Weight Loss Entry Make Merck (MRK) A Buy

Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche

Investor's Business Daily

a month ago

Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche

Merck moves into obesity with deal for Hansoh’s GLP-1 pill

BioPharma Dive

a month ago

Merck moves into obesity with deal for Hansoh’s GLP-1 pill

Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

Business Wire

a month ago

Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis

Benzinga

a month ago

Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis

Is Merck & Co., Inc. (MRK) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Insider Monkey

a month ago

Is Merck & Co., Inc. (MRK) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Merck targets 2025 RSV season with antibody now under FDA review

BioPharma Dive

a month ago

Merck targets 2025 RSV season with antibody now under FDA review

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

Business Wire

a month ago

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

Maternal mortality trends remain dire — and researchers face an uphill battle to solve them

Pharma Voice

a month ago

Maternal mortality trends remain dire — and researchers face an uphill battle to solve them

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab

Business Wire

a month ago

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab

MT Newswires

a month ago

Merck's KEYTRUDA Approved in Combination With Chemotherapy in China to Treat Lung Cancer

Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC

Business Wire

a month ago

Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma

Business Wire

a month ago

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma

How HP, Merck And Virtus Investment Partners Can Put Cash In Your Pocket

Benzinga

a month ago

How HP, Merck And Virtus Investment Partners Can Put Cash In Your Pocket

Possible Bearish Signals With Merck Insiders Disposing Stock

Simply Wall St.

a month ago

Possible Bearish Signals With Merck Insiders Disposing Stock

AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients

Benzinga

a month ago

AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients

MT Newswires

a month ago

AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients

LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial

Business Wire

a month ago

LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial

The Zacks Analyst Blog Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International

Zacks

a month ago

The Zacks Analyst Blog Alphabet, Oracle, Merck & Co, Canterbury Park and CompX International

Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?

Insider Monkey

a month ago

Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?

Top Analyst Reports for Alphabet, Oracle & Merck

Zacks

a month ago

Top Analyst Reports for Alphabet, Oracle & Merck

How Much Would It Take To Earn $100 A Month From Merck Stock

Benzinga

a month ago

How Much Would It Take To Earn $100 A Month From Merck Stock

Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer

Benzinga

a month ago

Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer

ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug

BioPharma Dive

a month ago

ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer

Business Wire

a month ago

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer

MT Newswires

a month ago

Merck's Study Shows Complete Response Rate of 100% for Zilovertamab Vedotin With R-CHP in Cancer Patients

Why Merck & Co. (MRK) Is the Best Beginner Stock to Invest in Now?

Insider Monkey

a month ago

Why Merck & Co. (MRK) Is the Best Beginner Stock to Invest in Now?

Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Business Wire

a month ago

Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Why Merck & Co. (MRK) Is Among the Best Affordable Stocks to Buy Right Now

Insider Monkey

2 months ago

Why Merck & Co. (MRK) Is Among the Best Affordable Stocks to Buy Right Now

Merck (NYSE:MRK) Will Pay A Larger Dividend Than Last Year At $0.81

Simply Wall St.

2 months ago

Merck (NYSE:MRK) Will Pay A Larger Dividend Than Last Year At $0.81

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

2 months ago

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Here’s What is Powering Merck & Co.’s (MRK) Earnings Growth

Insider Monkey

2 months ago

Here’s What is Powering Merck & Co.’s (MRK) Earnings Growth

Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults

Business Wire

2 months ago

Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults

Investing.com

2 months ago

HSBC upgrades Merck stock to Buy on 2025 opportunities

Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan

TipRanks

2 months ago

Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan

MT Newswires

2 months ago

HSBC Upgrades Merck to Buy, Price Target at $130

Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment

GuruFocus.com

2 months ago

Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment

FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations

Business Wire

2 months ago

FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations

Morningstar Research

2 months ago

Analyst Report: Merck & Co., Inc.

Why Is Merck & Co., Inc. (MRK) Among the Stocks Ray Dalio’s Bridgewater Is Crazy About?

Insider Monkey

2 months ago

Why Is Merck & Co., Inc. (MRK) Among the Stocks Ray Dalio’s Bridgewater Is Crazy About?

Merck & Co. (MRK) Fell As It Faced Some Demand Headwinds In China

Insider Monkey

2 months ago

Merck & Co. (MRK) Fell As It Faced Some Demand Headwinds In China

Share on Social Networks: